Indispensable role of microbes in anticancer drugs and discovery trends

Kapoor, Ridam; Saini, Anamika; Sharma, Deepika

doi:10.1007/s00253-022-12046-2

Cited by 9 publications

(3 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potent protein kinase C (PKC) inhibitor (IC 50 = 2.7 nM) staurosporine containing the indolo[2,3-a]carbazole structure was first discovered in S. staurosporeus in 1977 [18]. Lately, several analogues have been isolated and approved for clinical use, such as midostaurin and lestaurtinib [19]. Compounds 1-4 (Figure 3) are marine Streptomyces' staurosporine derivatives with significant selective inhibition of Rho-associated protein kinase (ROCK2), PKC and Brution tyrosine kinase (BTK) [20,21].…”

Section: Staurosporinesmentioning

confidence: 99%

Marine Streptomyces-Derived Novel Alkaloids Discovered in the Past Decade

Liu,

Sun,

et al. 2024

Marine Drugs

View full text Add to dashboard Cite

Natural alkaloids originating from actinomycetes and synthetic derivatives have always been among the important suppliers of small-molecule drugs. Among their biological sources, Streptomyces is the highest and most extensively researched genus. Marine-derived Streptomyces strains harbor unconventional metabolic pathways and have been demonstrated to be efficient producers of biologically active alkaloids; more than 60% of these compounds exhibit valuable activity such as antibacterial, antitumor, anti-inflammatory activities. This review comprehensively summarizes novel alkaloids produced by marine Streptomyces discovered in the past decade, focusing on their structural features, biological activity, and pharmacological mechanisms. Future perspectives on the discovery and development of novel alkaloids from marine Streptomyces are also provided.

show abstract

Section: Staurosporinesmentioning

confidence: 99%

Marine Streptomyces-Derived Novel Alkaloids Discovered in the Past Decade

Liu,

Sun,

et al. 2024

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…Researchers presented an overview of recent research and molecular explanations for the link between the gastrointestinal microbiota and the emergence of malignancies, which sheds light on potential therapeutic approaches for cancer detection, therapy, or avoidance. Among the most commonly utilized cancer chemotherapeutic medicines are microbe-derived antitumor antibiotics focused mostly on microbe-derived anticancer medications while considering their derivatives, biological mechanism, separation techniques, limits, and what kind of cancers they target [8]. The clinical significance of plasma cfRNAs produced from humans and microbes, as well as their prospective applications in the diagnosis of cancer and the localization of tumors, are demonstrated in a paper [9], as shown in Figure 2.…”

Section: The Connection Between Body's Microbes and Cancermentioning

confidence: 99%

Correlation Analysis Between Microbes And Human Diseases

Zhou¹

2023

HSET

View full text Add to dashboard Cite

The pathophysiology of human diseases has been shown to be strongly connected to a variety of microorganisms. The microbiome that inhabits the human bodies has a significant impact on our health, yet its relationship to disease remains poorly understood. Now, various microbial-based human illness networks have been created, examining the micro-to-macro link between microorganisms and disease. In addition, microbial-based disease analysis can anticipate new disease-microbe-drug correlations and processes. The prediction techniques and scientific achievements given could be used to solve intractable medical problems. On the basis of evidence that microbes have either been demonstrated to play pathogenic roles in promoting obesity, NAFLD, and cardiovascular illnesses, a link has been established between gut bacteria and the development of numerous diseases, both positively and negatively. How to better systematically comprehend the intricate connections between bacteria and hosts within the human body and develop novel tailored medications to tackle metabolic illnesses. Reduce the number or activity of dangerous microorganisms by encouraging the reconfiguration of the gut microbiota, or utilizing their activity to stimulate the growth of beneficial bacteria. Analyzing the pathogenic logic chain of microbes in various diseases, identifying the metabolic mechanism at the micro level, and developing more accurate methods for disease prediction.

show abstract

“…Food and Drug Administration (FDA)-approved chemotherapy drugs encompass alkylating agents, antimetabolites, antitumor antibiotics, kinase inhibitors, topoisomerase inhibitors, mitotic inhibitors, and corticosteroids [ 11 , 12 ]. Antitumor antibiotics derived from microorganisms are characterized by high efficiency and a broad spectrum, making them a significant component of clinical chemotherapy [ 13 ]. Bleomycin, actinomycin, doxorubicin, and streptozotocin are all classified as antitumor antibiotics and are extensively employed in the treatment of various cancers [ 14 – 17 ].…”

Section: Introductionmentioning

confidence: 99%

Targeted inhibition of the PI3K/AKT/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer

Li,

Cheng,

et al. 2024

Cell Mol Biol Lett

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC), characterized by low survival rates and a high recurrence rate, is a major cause of cancer-related mortality. Aberrant activation of the PI3K/AKT/mTOR signaling pathway is a common driver of NSCLC. Within this study, the inhibitory activity of (+)-anthrabenzoxocinone ((+)-ABX), an oxygenated anthrabenzoxocinone compound derived from Streptomyces, against NSCLC is demonstrated for the first time both in vitro and in vivo. Mechanistically, it is confirmed that the PI3K/AKT/mTOR signaling pathway is targeted and suppressed by (+)-ABX, resulting in the induction of S and G2/M phase arrest, apoptosis, and autophagy in NSCLC cells. Additionally, the augmentation of intracellular ROS levels by (+)-ABX is revealed, further contributing to the inhibition of the signaling pathway and exerting inhibitory effects on tumor growth. The findings presented in this study suggest that (+)-ABX possesses the potential to serve as a lead compound for the treatment of NSCLC. Graphical abstract

show abstract

Indispensable role of microbes in anticancer drugs and discovery trends

Cited by 9 publications

References 165 publications

Marine Streptomyces-Derived Novel Alkaloids Discovered in the Past Decade

Marine Streptomyces-Derived Novel Alkaloids Discovered in the Past Decade

Correlation Analysis Between Microbes And Human Diseases

Targeted inhibition of the PI3K/AKT/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer

Contact Info

Product

Resources

About